Skip to main content
Addgene

pBAD/HisB-PAiRFP2
(Plasmid #44271)

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 44271 Standard format: Plasmid sent in bacteria as agar stab 1 $85

Backbone

  • Vector backbone
    pBAD/HisB
  • Backbone manufacturer
    Invitrogen
  • Backbone size w/o insert (bp) 4064
  • Total vector size (bp) 4092
  • Vector type
    Bacterial Expression

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    DH5alpha
  • Copy number
    Low Copy

Gene/Insert

  • Gene/Insert name
    PAiRFP2
  • Alt name
    Photoactivatable iRFP2
  • Species
    Synthetic
  • Insert Size (bp)
    1537
  • Mutation
    K69R/R83K/G120D/A123T/M163L/Q168E/R220P/S243N/V244F/G269D/A276V/Y280C/V294A/H303F/H333R/I336L/D349R/M351I/A386V/G409D/L419I/T469S/A487T/E494G
  • Promoter pBAD

Cloning Information

  • Cloning method Restriction Enzyme
  • 5′ cloning site BglII (not destroyed)
  • 3′ cloning site AsuII (BstBI) (not destroyed)
  • 5′ sequencing primer atgccatagcatttttatcc
  • 3′ sequencing primer GAT TTA ATC TGT ATC AGG CTG
  • (Common Sequencing Primers)

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pBAD/HisB-PAiRFP2 was a gift from Vladislav Verkhusha (Addgene plasmid # 44271 ; http://n2t.net/addgene:44271 ; RRID:Addgene_44271)
  • For your References section:

    Far-red light photoactivatable near-infrared fluorescent proteins engineered from a bacterial phytochrome. Piatkevich KD, Subach FV, Verkhusha VV. Nat Commun. 2013 Jul 10;4:2153. doi: 10.1038/ncomms3153. 10.1038/ncomms3153 PubMed 23842578